Luminate

Phase 3Small molecule

Pfizer

Luminate is one of 89 small molecule programs targeting Prader-Willi syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prader-Willi SyndromeActive, not recruiting

InfluenzaActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Non-Proliferative Diabetic RetinopathyActive, not recruiting

Prader-Willi SyndromePhase 3

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Diabetic Macular EdemaPhase 2

Active, not recruiting

Non-Proliferative Diabetic RetinopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Luminate

Pfizer

Phase 3

1 2

Fluzone

Sanofi

Preclinical

16 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 5

COMIRNATY

Pfizer

Preclinical

1 6

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 7

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 8

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 9

MF-59

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1 10

Xuanfei Baidu Granule

PPeking University People's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Rotavirus Vaccine

NCT06962904

Clinical

Trials by Indication[1]

Rotavirus Vaccine2 trials

CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults

Completed·CCenters for Disease Control and Prevention·Phase 1·NCT06485258·50 enrolled

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

Active, not recruiting·CCenters for Disease Control and Prevention·Phase 1·NCT06962904·50 enrolled

Infiltration2 trials

Anesthetic Efficacy of 1.8 ml Versus 3.6 ml of 4% Articaine Buccal Infiltration

Unknown status·—·N/A·NCT06119139·70 enrolled

Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success

Unknown status·—·N/A·NCT05238727·75 enrolled

Prader-Willi syndrome1 trial

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome

Completed·LLevo Therapeutics, Inc.·Phase 3·NCT03649477·130 enrolled

Hemodynamic1 trial

Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics

Completed·MMauricio Jose Tornelli·Phase 4·NCT01719978·20 enrolled

Non-Proliferative Diabetic Retinopathy1 trial

A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy

Completed·AAllegro Ophthalmics, LLC·Phase 2·NCT02435862·105 enrolled

5 more indications

Influenza1 trial

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

Completed·BBiomedical Advanced Research and Development Authority·Phase 2·NCT06560151·1,380 enrolled

Intravenous Administration1 trial

Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA

Completed·ZZiekenhuis Oost-Limburg·Phase 2·NCT01940692·120 enrolled

Concentration1 trial

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT02066909·77 enrolled

Single Ascending Dose1 trial

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Completed·LLpath, Inc.·Phase 1·NCT02341508·36 enrolled

Diabetic Macular Edema1 trial

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Completed·AAllegro Ophthalmics, LLC·Phase 2·NCT02348918·218 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Luminate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Luminate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Luminate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Luminate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Rotavirus Vaccine2 trials

Infiltration2 trials

Prader-Willi syndrome1 trial

Hemodynamic1 trial

Non-Proliferative Diabetic Retinopathy1 trial

Influenza1 trial

Intravenous Administration1 trial

Concentration1 trial

Single Ascending Dose1 trial

Diabetic Macular Edema1 trial

References

Drug Info

Quick Facts

Related News